// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Improving Methotrexate Medication Documentation in Juvenile Idiopathic Arthritis

Buthaina Al Adba - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Clinical Effectiveness and Safety of Leflunomide in Inflammatory Arthritis: A Report from the RAPPORT Database

Stephanie Keeling - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

HWA-486

Clinical Effectiveness and Safety of Leflunomide in Inflammatory Arthritis: Patient Reported Data

Stephanie Keeling - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

HWA-486

Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from the Ontario Best Practice Research Initiatives Cohort

Mohammad Movahedi - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Leukotriene Receptor Antagonist Therapy Associated Eosinophilic Granulomatosis with Polyangiitis: A Case and Literature Review

Kimberly Legault - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Eosinophilic granulomatosis with polyangiitis

Montelukast

Primary and Secondary Non-Response in RA Patients Treated with an Anti-TNF: An Analysis from a Prospective, Observational Registry

Philip Baer - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

Infliximab

Duration of Bisphosphonate Therapy and the Risk of Atypical Femur Fracture in Rheumatic Disease Patients

Mary Bell - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoporosis

N/A

Attrition and Participant Characteristics in the Ontario Best Practices Research Initiative (OBRI)

Xiuying Li - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Knee Pain Intensity is Associated with Muscle Adiposity in the Whole Thigh and Hamstrings of Women with Knee Osteoarthritis

Peter Keir - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Knee osteoarthritis

N/A

Self-Management of RA Flares Varies by Severity and Duration: Results from CATCH

Clifton Bingham - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Autophagy Can Regulate the Unfolded Protein Response and Affect Pathogenesis of Ankylosing Spondylitis

Zhenbo Zhang - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

N/A

CHRNA7 Genetic Variants are Associated with Radiographic Severity and Progression in Ankylosing Spondylitis (AS)

Nigil Haroon - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

Mecasermin rinfabate

Understanding Erosions Inside-Out: Erosion Depth Predicts Bone Repair over 2 Years in Rheumatoid Arthritis

Michael Tomizza - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Determining the Minimal Clinically Important Difference for Systemic Lupus Erythematosus Disease Activity Index-2000 Responder Index-50 (S2K RI-50)

Dafna Gladman - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Histopathology of Childhood Small Vessel CNS Vasculitis

Maryam Nabavi Nouri - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Reliability Analysis of Two Short Medication Adherence Questionnaires in Patients with Rheumatoid Arthritis

Mary Bell - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Risk of Diabetes Mellitus in Rheumatoid Arthritis Associated with Medications Used in RA: A Population Based Cohort Study

Antonio Avina-Zubieta - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Rheumatoid arthritis

Methotrexate

Impact of MRI on Diagnostic Reclassification in Axial Spondyloarthritis: Data from the Screening for Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Study (SASPIC)

Dianne Mosher - Canadian Rheumatology Association (CRA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Axial spondyloarthritis

N/A

Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients in Canada: Interim Results from the ACT_UP CARE Study

Shahin Jamal - Canadian Rheumatology Association (CRA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Tocilizumab

What is the Correlation of Individual HAQ and BASDAI Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction

Michel Zummer - Canadian Rheumatology Association (CRA) , 2015

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

Infliximab

Copyright © 2026. QuantiNova All rights reserved